Sanofi, Sandoz Beat Cancer Patients’ Taxotere Hair Loss Suits

April 20, 2021, 4:39 PM UTC

Sanofi-Aventis and Sandoz defeated lawsuits by breast cancer patients who didn’t show that a warning about permanent hair loss would have changed their doctors’ decisions to prescribe Taxotere or a generic equivalent, under rulings from the Fifth Circuit and a Louisiana federal trial court.

Taxotere maker Sanofi-Aventis US Services Inc. was properly granted summary judgment in June Phillips’ lawsuit, the U.S. Court of Appeals for the Fifth Circuit said Monday.

Her oncologist testified that an additional warning regarding permanent hair loss hasn’t altered his risk-benefit assessment of Taxotere and wouldn’t have changed his decision to use the drug to treat ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.